Results 61 to 70 of about 12,617 (217)

MALIGNANT ARTERIAL HYPERTENSION IN A CHILD WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME

Мать и дитя в Кузбассе, 2022
Atypical hemolytic-uremic syndrome (aHUS) is a rare orphan disease. In the Altai Region, two cases of aHUS among children have been recorded. The disease is characterized by a severe course with high mortality, frequent development of complications and a
Олеся Алексеевна Зенченко, Евгений Васильевич Скударнов, Галина Ивановна Выходцева, Юлия Васильевна Волкова, Людмила Михайловна Новикова, Ольга Михайловна Малюга   +5 more
doaj  

Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology

Brazilian Journal of Nephrology, 2018
Scleroderma is an autoimmune disease that affects multiple systems. While pathophysiologic mechanisms governing the development of scleroderma are relatively poorly understood, advances in our understanding of the complement system are clarifying the ...
Roman Zuckerman, Arif Asif, Eric J. Costanzo, Tushar Vachharajani   +3 more
doaj   +1 more source

Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex [PDF]

, 2016
Introduction Coagulation and complement systems are simultaneously activated at sites of tissue injury, leading to thrombin generation and opsonisation with C3b.
Baerga-Ortiz, Bajzar, Boehme, Bossi, Campbell, Conway, de Córdoba S, Delvaeye, Dragon-Durey, Esmon, Esmon, Esmon, Esparza-Gordillo, Faust, Fuentes-Prior, Gordon, Hakobyan, Hamad, Harris, Heurich, Hindmarsh, Honda, Huntington, Ikeda, Ito, Jokiranta, Kavanagh, Li, Light, Maga, Markiewski, Martinez-Barricarte, Mayer, Meri, Mizuno, Moll, Morgan, Mouksassi, Noris, Owen, Pangburn, Sadler, Sadler, Saito, Salem, Sawada, Schramm, Shental-Bechor, Suzuki, Tateishi, Tortajada, Udagawa, Vincent, Walport, Walport, Wu, Yada, Yamamoto, Zushi   +58 more
core   +2 more sources

Atypical Hemolytic Uremic Syndrome: A Case Report [PDF]

Cureus, 2019
Hemoytic uremic syndrome (HUS) is a rare type of thrombotic microangiopathies. Manifestations include thrombocytopenia, microangiopathic hemolytic anemia, and thrombi in small blood vessels. The prognosis is poor. Herein, we present a case of atypical HUS, which is very rare.
Mohammed, Sohaib K, Mubarik, Ateeq, Nadeem, Bilal, Khan, Khudadad, Muddassir, Salman   +4 more
openaire   +2 more sources

Delayed‐Onset Hemolysis in a Case of Hemolytic Uremic Syndrome: A Diagnostic Challenge

Case Reports in Hematology, Volume 2026, Issue 1, 2026.
Background Hemolytic uremic syndrome is a rare thrombotic microangiopathy characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury. While commonly reported in children, adult‐onset presentations are less frequent and often atypical, leading to diagnostic delays.
Muhammad Younas, Noor Fatima, Zimal Naveed, Syeda Nafisa, Ana Antun   +4 more
wiley   +1 more source

Primary Thrombotic Microangiopathy in Pediatric Patients

Global Pediatric Health
Background . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology .
Andrés David Aranzazu Ceballos MD, Lina María Martínez Sánchez MSc, Ana Paulina Pamplona Sierra MD, Daniela Vergara Yánez MD, Liliana Franco Hincapié PhD, Richard Baquero Rodriguez MD   +5 more
doaj   +1 more source

MULTIFACTORIAL ETIOLOGY OF ATIPICAL HEMOLYTIC UREMIC SYNDROME-CASE REPORT [PDF]

Sanamed
Introduction: Hemolytic uremic syndromes are characterized by the simultaneous occurrence of hemolytic anemia, microangiopathy, thrombocytopenia, and acute renal insufficiency.
Skoric Jasmina, Klacar Uzelac Marija, Kostic Ana   +2 more
doaj   +1 more source

COVID-19 vaccination and Atypical hemolytic uremic syndrome

Frontiers in Immunology, 2022
IntroductionCOVID-19 vaccination has been associated with rare but severe complications characterized by thrombosis and thrombocytopenia.Methods and ResultsHere we present three patients who developed de novo or relapse atypical hemolytic uremic syndrome
Romy N. Bouwmeester, Esther M.G. Bormans, Caroline Duineveld, Arjan D. van Zuilen, Anne-Els van de Logt, Jack F.M. Wetzels, Nicole C.A.J. van de Kar   +6 more
doaj   +1 more source

Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizimab treatment [PDF]

, 2016
Background: Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS). Guidelines discuss the importance of prompt treatment. We report a post hoc analysis investigating the effect of baseline factors, including patient characteristics and ...
Ardissimo, Gianluigi, Delmas, Yahsou, Haller, Herman, Kincaid, John F, Vande Walle, Johan, Wang, Jimmy   +5 more
core   +2 more sources

Evaluating the Real‐World Safety of Ravulizumab in Generalized Myasthenia Gravis: Insights From a Detailed Analysis of FAERS Data

Journal of Clinical Pharmacy and Therapeutics, Volume 2026, Issue 1, 2026.
Background Ravulizumab represents the inaugural long‐acting complement C5 inhibitor that has received approval in various countries around the globe for individuals diagnosed with generalized myasthenia gravis (gMG) who are positive for anti‐acetylcholine receptor antibodies.
Yakun Wang, Qian Guo, Jiayu Bai, Jiaqi Shi, Ziquan Yang, Hongda Liu   +5 more
wiley   +1 more source